Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives

References

• Bailey JA. Concise dictionary of medical—legal terms. New York: The Parthanon Publishing Group; 1998.
   Google Scholar
• Gospodarowicz MK, O'Sullivan B. Prognostic factors: principles and application. In: Gospodarowicz MK, Henson, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch, editors. Prognostic factors in cancer, 2nd ed. New York: Wiley-Liss; 2001. p. 17–35.
   Google Scholar
• Burke HB. Increasing the power of surrogate endpoint biomarkers: the aggregation of predictive factors. J Cell Biochem Suppl 1994;19:278–82.
   PubMedGoogle Scholar
• Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206–19.
   Google Scholar
• Henderson IC, Patek AJ. The relationship between prog-nostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998;52:261–88.
   PubMed Web of Science ®Google Scholar
• Dixon FJ, Moore RA. Tumors of the male sex organs. Atlas of tumor pathology, series 1, fascicle 32. Washington D.C.: Armed Forces Institute of Pathology; 1952. p. 10.
   Google Scholar
• Whitmore WF Jr. Hormone therapy and prostate cancer. Am J Med 1956;697:613.
   Google Scholar
• Jewett HJ. The present status of radical prostatectomy for stage A and B prostate cancer. Urol Clin North Am 1975;2:105–24.
   PubMedGoogle Scholar
• Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual, 6th ed. New York: Springer Verlag; 2002.
   Google Scholar
• Broders AC. Squamous cell epithelioma of the lip. JANIA 1920;74:656–64.
   Google Scholar
• Young HH, Davis DM. Young's practice of urology. Phila-delphia, PA: Saunders; 1926.
   Google Scholar
• Muir EG. Carcinoma of the prostate. Lancet 1934;i:667–72.
   Google Scholar
• Humphrey PA. Prostate pathology. Chicago, IL: ASCP Press; 2003. p. 339.
   Google Scholar
• Mostofi FK. Grading of prostate carcinoma. Cancer Che-mother Rep 1975;59:111–7.
   PubMedGoogle Scholar
• Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours. International histological classification of tumours, 22. Geneva, Switzerland: World Health Organiza-tion; 1980.
   Google Scholar
• Gleason DF. Classification of prostatic carcinoma. Cancer Chemother Rep 1966;50:125–8.
   PubMedGoogle Scholar
• Mellinger GT, Gleason D, Bailar Jill. The histology and prognosis of prostatic cancer. J Urol 1967;97:331–7.
   Google Scholar
• Gleason DF, Veterans Administration Cooperative Urologi-cal Research Group. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia, PA: Lea & Febiger; 1977. p. 171–97.
   Google Scholar
• Young RH, Srigley JR, Amin MB, et al. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. Atlas of tumor pathology, 3rd series, fascicle 28. Washington D.C.: American Registry of Pathology; 2000.
   Google Scholar
• Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics. Tumors of the urinary system and male genital organs. WHO classification of tumors. Lyon, France: IARC Press; 2004.
   Google Scholar
• Srigley JR, Amin MB, Bostwick DG, et al. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists, Arch Pathol Lab Med 2000;124:1034–9.
   Google Scholar
• Amin MB, Grignon DJ, Humphrey PA, et al. Gleason grading of prostate cancer. A contemporary approach. Philadelphia, PA: Lippincott, Williams and Wilkins; 2004.
   Google Scholar
• Fossa SD, Paus E, Lindegaard M, et al. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br J Urol 1992;69:175–9.
   PubMedGoogle Scholar
• Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 1994;21:613–9.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Fleshner NE, Soloway SM, et al. Prognostic significance of prostate-specific antigen in stage Tic prostate cancer treated by radical prostatectomy. Urology 1997;49:887–97.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, et al. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial. J Clin Oncol 1997;15:1465–9.
   PubMed Web of Science ®Google Scholar
• Partin AW, Nathan MW, Subong ENP. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JANIA 1997;277:145–51.
   Google Scholar
• American Society of Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. hit J Radiat Oncol Biol Phys 1997;37:1035–41.
   PubMed Web of Science ®Google Scholar
• jani AB, Chen MH, Vaida F, et al. PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention. Urology 1999;554:700–5.
   Google Scholar
• Critz FA, Williams WH, Holladay CT, et al. Post-treatment PSA 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 1999;54: 968–71.
   Google Scholar
• Palmberg C, Koivisto P, Visakorpi T, et al. PSA decline is an independent prognostic marker in hormonally treated pros-tate cancer. Eur Urol 1999;36:191–6.
   PubMed Web of Science ®Google Scholar
• Zagars GK, Sands ME, Pollack A, et al. Early androgen ablation for stage D1 (N1TON3,M0) prostate cancer: prognostic variable and outcome. J Urol 1999;151:1330–3.
   Google Scholar
• Bostwick DG, Foster CS. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second Interna-tional Consultation on Prostate Cancer. Semin Urol Oncol 1999;17:222–72.
   PubMedGoogle Scholar
• Bostwick DG, Grignon DG, Hammond EH, et al. Prog-nostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124: 995–1000.
   Google Scholar
• Gleason DF, Mellinger GT. The Veterans Administration Cooperative Urological Research Group: prediction of prognosis for prostatic carcinoma by combined histological grading and clinical staging. J Urol 1974;111:58–64.
   PubMed Web of Science ®Google Scholar
• Burke HB, Henson DE. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72:3131–5.
   PubMed Web of Science ®Google Scholar
• McShane LM, Simon R. Statistical methods for the analysis of prognostic factor studies. In: Gospodarowicz MK, Hen-sen DE, Hutter REP, et al., editors. Prognostic factors in cancer, 2nd ed. New York: Wiley-Liss; 2001. p. 49–56.
   Google Scholar
• Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352–9.
   PubMed Web of Science ®Google Scholar
• Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urol-ogy 2001;58:393–9.
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton ANIF, et al. A pre-operative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.
   PubMed Web of Science ®Google Scholar
• Burke HB, Goodman PH, Rosen DB, et al. Artificial neural networks improve the accuracy of cancer survival prediction. Cancer 1997;79:857–62.
   PubMed Web of Science ®Google Scholar
• Diagnosis and prognostic parameters in localized prostate cancer. Scand J Urol Nephrol Suppl 1994;162:1–127.
   Google Scholar
• Henson DE, Fielding LP, Grignon DJ, et al. College of American Pathologists Conference XXVI on Clinical Rele-vance of Prognostic Markers in Solid Tumors. Arch Pathol Lab Med 1995;119:1109–12.
   PubMed Web of Science ®Google Scholar
• Grignon DJ, Hammond EH. College of American Patholo-gists Conference XXVI on Clinical Relevance of Prognostic Markers in Solid Tumors. Arch Pathol Lab Med 1995;119:1122–6.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Fitzgibbons PL, Compton CC, et al. College of American Pathologists Conference XXXV: Solid Tumor Prognostic Factors-Which, How and So What? Arch Pathol Lab Med 2000;124:958–65.
   PubMed Web of Science ®Google Scholar
• Montie JE. Current prognostic factors for prostate carci-noma. Cancer 1996;78:341–4.
   PubMed Web of Science ®Google Scholar
• Hutter RVP, Montie JE, Busch D, et al. Current prognostic factors and their relevance to staging. Cancer 1996;78:369–71.
   PubMed Web of Science ®Google Scholar
• Von Eschenbach AC, Brawer MK, di Sant'Agnese A, et al. Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. Cancer 1996;78:372–5.
   Google Scholar
• Hermanek PK, Gospodarowicz MK, Henson DE, et al., editors. Prognostic factors in cancer. Berlin: Springer-Verlag; 1995.
   Google Scholar
• Gospodarowicz MK, Henson DE, Hutter RVP, et al., editors. Prognostic factors in cancer, 2nd ed. New York: Wiley-Liss; 2001.
   Google Scholar
• Marchevsky AM, Wick MR. Evidence-based medicine, medical decision analysis, and pathology. Hum Pathol 2004;35:1179–88.
   PubMed Web of Science ®Google Scholar